secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2026-09-08T20:54:32+00:00
Accession:  0001193125-26-385331
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx enters avexitide supply agreements with Bachem and Polypeptide; $30M upfront to Polypeptide
--------------------------------------------------------------------------------

- Paid or agreed $30M upfront fee to Polypeptide for capacity reservation under term sheet.
- Bachem Manufacturing Agreement begins 2028 with minimum annual purchase quantities of avexitide drug substance.
- Both suppliers are non-exclusive; Amylyx may use alternate manufacturers.
- Supply prices adjusted annually for labor, utilities, overhead; terms auto-renew after 5 years.
- Agreements cover commercial manufacturing of avexitide if regulatory approval is obtained.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000119312526385331/0001193125-26-385331-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000119312526385331/d160615d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-385331

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer